Ronifibrate

This classification denotes an anti-lipidemic agent with the molecular formula C19H20ClNO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W86I18X716, chemically known as 3-pyridinecarboxylic acid, 3-(2-(4-chlorophenoxy)-2-methyl-1-oxopropoxy)propyl ester but generally known as ronifibrate, which bears US NIH Compound Identifier 68671. European Medicines Agency schedules Ronifibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10378MIG. The term RONIFIBRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules ronifibrate in its Anatomical Therapeutic Chemical (ATC) Classification. RONIFIBRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ronifibrate under HS 29333999 and SITC 51574. As of Q4 2014, RONIFIBRATE remains the US FDA Preferred Term for this commodity. Ronifibrate bears US NLM identifiers UMLS ID C2347974 and NCI Concept Code C72995. SMILES: Clc1ccc(OC(C)(C)C(=O)OCCCOC(=O)c2cccnc2)cc1.